DaVita (NYSE:DVA) Releases FY 2024 Earnings Guidance

DaVita (NYSE:DVA) issued an update on its FY 2024 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 9.000-9.800 for the period, compared to the consensus estimate of 9.010. The company issued revenue guidance of -.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. UBS Group boosted their target price on shares of DaVita from $113.00 to $134.00 and gave the stock a buy rating in a research note on Wednesday, February 14th. TheStreet raised DaVita from a c+ rating to a b- rating in a research note on Wednesday, February 7th. StockNews.com raised DaVita from a buy rating to a strong-buy rating in a research note on Thursday, April 25th. Barclays lifted their target price on shares of DaVita from $133.00 to $150.00 and gave the stock an equal weight rating in a research note on Monday. Finally, Truist Financial raised their price target on shares of DaVita from $130.00 to $135.00 and gave the stock a hold rating in a research note on Tuesday, February 20th. Two analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of Moderate Buy and a consensus price target of $121.33.

DaVita Trading Up 1.8 %

NYSE DVA traded up $2.42 during trading hours on Monday, reaching $136.87. The company had a trading volume of 1,433,893 shares, compared to its average volume of 846,295. The company has a current ratio of 1.43, a quick ratio of 1.37 and a debt-to-equity ratio of 7.95. The stock has a market capitalization of $12.00 billion, a P/E ratio of 15.49, a price-to-earnings-growth ratio of 1.17 and a beta of 1.04. The stock has a 50-day moving average of $133.71 and a 200 day moving average of $113.08. DaVita has a 1-year low of $71.51 and a 1-year high of $145.04.

DaVita (NYSE:DVA) last announced its earnings results on Thursday, May 2nd. The company reported $2.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.95 by $0.43. DaVita had a return on equity of 68.52% and a net margin of 6.61%. The company had revenue of $3.07 billion for the quarter, compared to analyst estimates of $3.03 billion. During the same quarter in the previous year, the company earned $1.58 earnings per share. The firm’s quarterly revenue was up 6.9% compared to the same quarter last year. As a group, research analysts anticipate that DaVita will post 9.49 earnings per share for the current fiscal year.

Insider Activity at DaVita

In related news, insider James O. Hearty sold 26,164 shares of DaVita stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $119.64, for a total value of $3,130,260.96. Following the completion of the transaction, the insider now owns 20,264 shares in the company, valued at $2,424,384.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Javier Rodriguez sold 67,603 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $126.11, for a total value of $8,525,414.33. Following the sale, the chief executive officer now owns 488,697 shares of the company’s stock, valued at $61,629,578.67. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider James O. Hearty sold 26,164 shares of the firm’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $119.64, for a total transaction of $3,130,260.96. Following the completion of the sale, the insider now owns 20,264 shares in the company, valued at $2,424,384.96. The disclosure for this sale can be found here. Insiders sold 134,540 shares of company stock worth $16,551,071 in the last three months. 1.40% of the stock is owned by company insiders.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.